Double blind trial of miconazole in dermatomycosis

Abstract

A double blind study of miconazole (Brentan) has been performed in 86 patients suffering from dermatomycosis. Of the 65 patitents not lost to follow up, 30 had received the active drug, and 35 placebo. The cure rate was significantly (p = 0.03) higher in patients receiving miconazole (70%) than in those on placebo (40%). The higher cure rate was found in patients suffering from cutaneous candidiasis and tinea versicolor, as well as from dermatophytosis, but was significant only in the latter group, which was the largest.